Sign up for email alert when new content gets added: Sign up
William Clearfield
American Osteopathic Society of Rheumatic Diseases, USA
Keynote: Gen surg: Open Access
Now affecting upwards of 1.7% of children born in the United States in 2018, a 15 percent increase in just the past two years, autism spectrum disorders (ASD) represents a significant, increasingly prevalent collection of neurodevelopmental disorders. (1-2) Characterized by marked impairments in social interaction, communication, and abnormal repetitive and stereotypical behaviors, autism’s earliest sig, at 1-3 months and 6-14 months, is rapid head growth. In our world, of course, rapid head growth results from elevated growth hormone (GH) levels. (3) GH levels are notoriously high in the autistic spectrum child. Yet numerous researchers report successful outcomes with IGF-1, the downstream active component of growth hormone therapy. And here is the disconnect. Adding IGF-1 should worsen the condition. It does not. ASD patients’ inflammatory cytokine profile, on average, results in elevated IL-6 cytokines in the bloodstream and cerebrospinal fluid. Excess growth hormone causes an elevation in Il-6. Il-6 interferes with the GH/IGF-1 conversion. Remedies discussed include medications (including increlex (IGF-1), intranasal insulin, low dose naltrexone, verapamil (off label), pioglitazone (off label), and the statins) and herbs and supplements (including EPA/DHA, ECGC, Vitamin C, NAC, quercetin, luteolin, and rutin. Objectives: 1. Chronic Inflammation as a Model for Autism. 2. Autism vs. TBI vs. Chronic Inflammation as an Age Management Entity 3. The Ah-Ha! Moment: “Executive Function” Deficiencies in TBI and ASD as a leading indicator of Chronic Inflammation 4. Review Growth Hormone/IGF-1 Physiology and its’ disconnect as a pro-inflammatory condition 5. Tips, Tricks, and Doozer Sticks: What I’ve Learned and What Every Practitioner Can Use from the Hormonal, Neurotransmitter and Cytokine Abnormalities Found in the Autistic Spectrum In the Context of Age Management 6. 5 Repurposed FDA Approved Medications, and How They Remedy Chronic Inflammation
William Clearfield, a graduate of LaSalle College, completed his medical training at the College of Osteopathic Medicine and Surgery, now Des Moines University in Des Moines, IA. He completed a rotating internship and served as an OB/GYN resident at Metropolitan Hospital, Philadelphia, PA and a Family Practice resident in 1982 at United Health and Hospital Services in Kingston, PA. He was certified by the American Board of Family Medicine and opened a private practice devoted to family and integrative medicine. Dr. Clearfield obtained a certificate degree in Cardiac Rehabilitation from the University of Wisconsin/Lacrosse and implemented a supervised diet and exercise program for cardiac patients at Nesbitt Hospital in Kingston, PA. Dr. Clearfield graduated from UCLA’s “Acupuncture for Physicians” program, served as Secretary of the American Academy of Medical Acupuncture, and was editor of the journal “Medical Acupuncture” from 1994 through 1996. In 1994, Dr. Clearfield established the first combined conventional and alternative medicine pain clinic at John Heinz Rehabilitation Hospital in Wilkes-Barre, PA. In 2002 Dr. Clearfield attended a workshop with instruction on testosterone hormone replacement implants and neuromodulators for facial rejuvenation, and his career took a different direction. Dr. Clearfield studied the intricacies and subtleties of anti-aging and wellness and safe hormone replacement therapy. He became a leading authority with many speaking engagements and publications throughout the United States. Also, Dr. Clearfield trained and in turn became an instructor in neuromodulator, dermal filler, laser therapies, the PDO Thread Lift, and Platelet Rich Plasma techniques, including facial, joint, genitourinary rejuvenation and is certified as a “Vampire” technique practitioner. Dr. Clearfield is one of three Nevada Delegates to the American Osteopathic Association’s House of Delegates and the Executive Director of the American Osteopathic Society of Rheumatic Diseases. He lectures extensively for A4M, the Nevada Osteopathic Medical Association, the Age Management Medicine Group, and along with Dr. Pamela Smith, presented a breakthrough six-hour mini-course on Bioidentical Hormone Therapy in 2017 at OMED, the American Osteopathic Association’s scientific conference in Philadelphia. So successful was this course, Dr. Clearfield expanded the curriculum to eight hours at OMED in San Diego, CA in October 2018.
